Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients’ Outcome

Author(s): Karthikeyan Subbarayan , Barbara Seliger* .

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 3 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The small leucine-rich proteoglycans (SLRPs) biglycan (BGN) and decorin (DCN) linked with sulfated glycosaminoglycan (GAG) chains exhibit oncogenic or tumor suppressive potentials depending on the cellular context and association with GAGs.

Objective: We hypothesized that structural alterations and expression levels of BGN, DCN and their associated chondroitin sulfate (CS) polymerizing enzymes, dermatan sulfate (DS) epimerases and various sulfatases might be correlated with the tumor (sub)type and patients’ survival.

Methods: We acquired breast cancer (BC) and glioma patients’ datasets from cBioPortal and R2 Genomics. Structural alterations and the expression pattern of CS polymerizing enzymes, DS epimerases and carbohydrate sulfotransferases (CHST) were compared to that of BGN and DCN and correlated to their clinical relevance.

Results: In BC, no mutations, but amplifications (0.2 – 2.1 %) and deletions (0.05 – 0.4 %) were found in BGN, DCN and CS/DS enzymes. In contrast, missense and/or truncated mutations (0.1 – 0.5 %), but a reduced amplification rate (0 – 1.5 %) were found in glioma. When compared to BC, the structural abnormalities caused altered mRNA expression levels of BGN, DCN, GAG synthesizing enzymes and CHST. Mutations in SLPRs, CHSY1, CHST4 and CHSY3 were correlated with a poor prognosis in glioma, while lack of mutations and copy number variations in the SLRPs, CHSY3, CHST15 and DSE displayed an increased survival in BC.

Conclusion: A distinct association of BGN and DCN with CHST, CS polymerizing enzymes and DS epimerases was found in BC and glioma. Thus, a unique pattern of structural alterations and expression, which has clinical relevance, was found for PGs and GAG synthesizing enzymes and CHST in BC and glioma, which might help to identify high-risk patients and to develop personalized therapeutics.

Keywords: Proteoglycans, glycosaminoglycan modification enzymes, cancer, breast cancer, glioma, prognostic marker.

[1]
Cancer Genome Atlas Research Network. Weinstein, J.N.; Collisson, E.A.; Mills, G.B.; Shaw, K.R.M.; Ozenberger, B.A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J.M.; Chu, A.; Chuah, E.; Chun, H.-J.E.; Dhalla, N.; Guin, R.; Hirst, M.; Hirst, C.; Holt, R.A.; Jones, S.J.M.; Lee, D.; Li, H.I.; Marra, M.A.; Mayo, M.; Moore, R.A.; Mungall, A.J.; Robertson, A.G.; Schein, J.E.; Sipahimalani, P.; Tam, A.; Thiessen, N.; Varhol, R.J.; Beroukhim, R.; Bhatt, A.S.; Brooks, A.N.; Cherniack, A.D.; Freeman, S.S.; Gabriel, S.B.; Helman, E.; Jung, J.; Meyerson, M.; Ojesina, A.I.; Pedamallu, C.S.; Saksena, G.; Schumacher, S.E.; Tabak, B.; Zack, T.; Lander, E.S.; Bristow, C.A.; Hadjipanayis, A.; Haseley, P.; Kucherlapati, R.; Lee, S.; Lee, E.; Luquette, L.J.; Mahadeshwar, H.S.; Pantazi, A.; Parfenov, M.; Park, P.J.; Protopopov, A.; Ren, X.; Santoso, N.; Seidman, J.; Seth, S.; Song, X.; Tang, J.; Xi, R.; Xu, A.W.; Yang, L.; Zeng, D.; Auman, J.T.; Balu, S.; Buda, E.; Fan, C.; Hoadley, K.A.; Jones, C.D.; Meng, S.; Mieczkowski, P.A.; Parker, J.S.; Perou, C.M.; Roach, J.; Shi, Y.; Silva, G.O.; Tan, D.; Veluvolu, U.; Waring, S.; Wilkerson, M.D.; Wu, J.; Zhao, W.; Bodenheimer, T.; Hayes, D.N.; Hoyle, A.P.; Jeffreys, S.R.; Mose, L.E.; Simons, J. V; Soloway, M.G.; Baylin, S.B.; Berman, B.P.; Bootwalla, M.S.; Danilova, L.; Herman, J.G.; Hinoue, T.; Laird, P.W.; Rhie, S.K.; Shen, H.; Triche, T.; Weisenberger, D.J.; Carter, S.L.; Cibulskis, K.; Chin, L.; Zhang, J.; Getz, G.; Sougnez, C.; Wang, M.; Saksena, G.; Carter, S.L.; Cibulskis, K.; Chin, L.; Zhang, J.; Getz, G.; Dinh, H.; Doddapaneni, H.V.; Gibbs, R.; Gunaratne, P.; Han, Y.; Kalra, D.; Kovar, C.; Lewis, L.; Morgan, M.; Morton, D.; Muzny, D.; Reid, J.; Xi, L.; Cho, J.; DiCara, D.; Frazer, S.; Gehlenborg, N.; Heiman, D.I.; Kim, J.; Lawrence, M.S.; Lin, P.; Liu, Y.; Noble, M.S.; Stojanov, P.; Voet, D.; Zhang, H.; Zou, L.; Stewart, C.; Bernard, B.; Bressler, R.; Eakin, A.; Iype, L.; Knijnenburg, T.; Kramer, R.; Kreisberg, R.; Leinonen, K.; Lin, J.; Liu, Y.; Miller, M.; Reynolds, S.M.; Rovira, H.; Shmulevich, I.; Thorsson, V.; Yang, D.; Zhang, W.; Amin, S.; Wu, C.-J.; Wu, C.- C.; Akbani, R.; Aldape, K.; Baggerly, K.A.; Broom, B.; Casasent, T.D.; Cleland, J.; Creighton, C.; Dodda, D.; Edgerton, M.; Han, L.; Herbrich, S.M.; Ju, Z.; Kim, H.; Lerner, S.; Li, J.; Liang, H.; Liu, W.; Lorenzi, P.L.; Lu, Y.; Melott, J.; Mills, G.B.; Nguyen, L.; Su, X.; Verhaak, R.; Wang, W.; Weinstein, J.N.; Wong, A.; Yang, Y.; Yao, J.; Yao, R.; Yoshihara, K.; Yuan, Y.; Yung, A.K.; Zhang, N.; Zheng, S.; Ryan, M.; Kane, D.W.; Aksoy, B.A.; Ciriello, G.; Dresdner, G.; Gao, J.; Gross, B.; Jacobsen, A.; Kahles, A.; Ladanyi, M.; Lee, W.; Lehmann, K.-V.; Miller, M.L.; Ramirez, R.; Rätsch, G.; Reva, B.; Sander, C.; Schultz, N.; Senbabaoglu, Y.; Shen, R.; Sinha, R.; Sumer, S.O.; Sun, Y.; Taylor, B.S.; Weinhold, N.; Fei, S.; Spellman, P.; Benz, C.; Carlin, D.; Cline, M.; Craft, B.; Ellrott, K.; Goldman, M.; Haussler, D.; Ma, S.; Ng, S.; Paull, E.; Radenbaugh, A.; Salama, S.; Sokolov, A.; Stuart, J.M.; Swatloski, T.; Uzunangelov, V.; Waltman, P.; Yau, C.; Zhu, J.; Hamilton, S.R.; Getz, G.; Sougnez, C.; Abbott, S.; Abbott, R.; Dees, N.D.; Delehaunty, K.; Ding, L.; Dooling, D.J.; Eldred, J.M.; Fronick, C.C.; Fulton, R.; Fulton, L.L.; Kalicki-Veizer, J.; Kanchi, K.-L.; Kandoth, C.; Koboldt, D.C.; Larson, D.E.; Ley, T.J.; Lin, L.; Lu, C.; Magrini, V.J.; Mardis, E.R.; McLellan, M.D.; McMichael, J.F.; Miller, C.A.; O’Laughlin, M.; Pohl, C.; Schmidt, H.; Smith, S.M.; Walker, J.; Wallis, J.W.; Wendl, M.C.; Wilson, R.K.; Wylie, T.; Zhang, Q.; Burton, R.; Jensen, M.A.; Kahn, A.; Pihl, T.; Pot, D.; Wan, Y.; Levine, D.A.; Black, A.D.; Bowen, J.; Frick, J.; Gastier- Foster, J.M.; Harper, H.A.; Helsel, C.; Leraas, K.M.; Lichtenberg, T.M.; McAllister, C.; Ramirez, N.C.; Sharpe, S.; Wise, L.; Zmuda, E.; Chanock, S.J.; Davidsen, T.; Demchok, J.A.; Eley, G.; Felau, I.; Ozenberger, B.A.; Sheth, M.; Sofia, H.; Staudt, L.; Tarnuzzer, R.; Wang, Z.; Yang, L.; Zhang, J.; Omberg, L.; Margolin, A.; Raphael, B.J.; Vandin, F.; Wu, H.-T.; Leiserson, M.D.M.; Benz, S.C.; Vaske, C.J.; Noushmehr, H.; Knijnenburg, T.; Wolf, D.; Veer, L.V.; Collisson, E.A.; Anastassiou, D.; Yang, T.-H.O.; Lopez- Bigas, N.; Gonzalez-Perez, A.; Tamborero, D.; Xia, Z.; Li, W.; Cho, D.-Y.; Przytycka, T.; Hamilton, M.; McGuire, S.; Nelander, S.; Johansson, P.; Jörnsten, R.; Kling, T.; Sanchez, J.; Weinstein, J.N.; Collisson, E.A.; Mills, G.B.; Shaw, K.R.M.; Ozenberger, B.A.; Ellrott, K.; Shmulevich, I.; Sander, C.; Stuart, J.M. The cancer genome atlas pan-cancer analysis project. Nat. Genet., 2013, 45, 1113-1120.
[2]
Afratis N, Gialeli C, Nikitovic D, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 2012; 279: 1177-97.
[3]
Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 1990; 38: 1549-63.
[4]
LeBaron RG, Esko JD, Woods A, Johansson S, Höök M. Adhesion of glycosaminoglycan-deficient chinese hamster ovary cell mutants to fibronectin substrata. J Cell Biol 1988; 106: 945-52.
[5]
Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986; 55: 1037-57.
[6]
Esko JD, Rostand KS, Weinke JL. Tumor formation dependent on proteoglycan biosynthesis. Science 1988; 241: 1092-6.
[7]
Andrlová H, Mastroianni J, Madl J, et al. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget 2017; 8: 42901-16.
[8]
Hu L, Zang M, Wang H-X, et al. Biglycan stimulates VEGF expression in endothelial cells by activating the TLR signaling pathway. Mol Oncol 2016; 10: 1473-84.
[9]
Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 2008; 27: 700-8.
[10]
Subbarayan K, Leisz S, Wickenhauser C, et al. Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. OncoImmunology 2017; e1373233.
[11]
Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. Am J Pathol 2012; 181: 380-7.
[12]
Troup S, Njue C, Kliewer EV, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003; 9: 207-14.
[13]
Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001; 20: 7437-46.
[14]
Chatzinikolaou G, Nikitovic D, Stathopoulos EN, Velegrakis GA, Karamanos NK, Tzanakakis GN. Protein tyrosine kinase and estrogen receptor-dependent pathways regulate the synthesis and distribution of glycosaminoglycans/proteoglycans produced by two human colon cancer cell lines. Anticancer Res 27: 4101-6.
[15]
Nikitovic D, Chatzinikolaou G, Tsiaoussis J, Tsatsakis A, Karamanos NK, Tzanakakis GN. Insights into targeting colon cancer cell fate at the level of proteoglycans / glycosaminoglycans. Curr Med Chem 2012; 19: 4247-58.
[16]
Curtis C, Shah SP, Chin S-F, et al. C.; Langerød, A.; Green, A.; Provenzano, E.; Wishart, G.; Pinder, S.; Watson, P.; Markowetz, F.; Murphy, L.; Ellis, I.; Purushotham, A.; Børresen-Dale, A.-L.; Brenton, J.D.; Tavaré, S.; Caldas, C.; Aparicio, S.; Chin, S.-F.; Curtis, C.; Ding, Z.; Gräf, S.; Jones, L.; Liu, B.; Lynch, A.G.; Papatheodorou, I.; Sammut, S.J.; Wishart, G.; Aparicio, S.; Chia, S.; Gelmon, K.; Huntsman, D.; McKinney, S.; Speers, C.; Turashvili, G.; Watson, P.; Ellis, I.; Blamey, R.; Green, A.; Macmillan, D.; Rakha, E.; Purushotham, A.; Gillett, C.; Grigoriadis, A.; Pinder, S.; di Rinaldis, E.; Tutt, A.; Murphy, L.; Parisien, M.; Troup, S.; Caldas, C.; Chin, S.-F.; Chan, D.; Fielding, C.; Maia, A.-T.; McGuire, S.; Osborne, M.; Sayalero, S.M.; Spiteri, I.; Hadfield, J.; Aparicio, S.; Turashvili, G.; Bell, L.; Chow, K.; Gale, N.; Huntsman, D.; Kovalik, M.; Ng, Y.; Prentice, L.; Caldas, C.; Tavaré, S.; Curtis, C.; Dunning, M.J.; Gräf, S.; Lynch, A.G.; Rueda, O.M.; Russell, R.; Samarajiwa, S.; Speed, D.; Markowetz, F.; Yuan, Y.; Brenton, J.D.; Aparicio, S.; Shah, S.P.; Bashashati, A.; Ha, G.; Haffari, G.; McKinney, S.; Langerød, A.; Green, A.; Provenzano, E.; Wishart, G.; Pinder, S.; Watson, P.; Markowetz, F.; Murphy, L.; Ellis, I.; Purushotham, A.; Børresen-Dale, A.-L.; Brenton, J.D.; Tavaré, S.; Caldas, C.; Aparicio, S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-52.
[17]
Pereira B, Chin S-F, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 2016; 7: 11479.
[18]
Ceccarelli M, Barthel FP, Malta TM, et al. TCGA Research Network, H.; Noushmehr, H.; Iavarone, A.; Verhaak, R.G.W.; Arachchi, H.; Auman, J.T.; Balasundaram, M.; Balu, S.; Barnett, G.; Baylin, S.; Bell, S.; Benz, C.; Bir, N.; Black, K.L.; Bodenheimer, T.; Boice, L.; Bootwalla, M.S.; Bowen, J.; Bristow, C.A.; Butterfield, Y.S.N.; Chen, Q.-R.; Chin, L.; Cho, J.; Chuah, E.; Chudamani, S.; Coetzee, S.G.; Cohen, M.L.; Colman, H.; Couce, M.; D’Angelo, F.; Davidsen, T.; Davis, A.; Demchok, J.A.; Devine, K.; Ding, L.; Duell, R.; Elder, J.B.; Eschbacher, J.M.; Fehrenbach, A.; Ferguson, M.; Frazer, S.; Fuller, G.; Fulop, J.; Gabriel, S.B.; Garofano, L.; Gastier-Foster, J.M.; Gehlenborg, N.; Gerken, M.; Getz, G.; Giannini, C.; Gibson, W.J.; Hadjipanayis, A.; Hayes, D.N.; Heiman, D.I.; Hermes, B.; Hilty, J.; Hoadley, K.A.; Hoyle, A.P.; Huang, M.; Jefferys, S.R.; Jones, C.D.; Jones, S.J.M.; Ju, Z.; Kastl, A.; Kendler, A.; Kim, J.; Kucherlapati, R.; Lai, P.H.; Lawrence, M.S.; Lee, S.; Leraas, K.M.; Lichtenberg, T.M.; Lin, P.; Liu, Y.; Liu, J.; Ljubimova, J.Y.; Lu, Y.; Ma, Y.; Maglinte, D.T.; Mahadeshwar, H.S.; Marra, M.A.; McGraw, M.; McPherson, C.; Meng, S.; Mieczkowski, P.A.; Miller, C.R.; Mills, G.B.; Moore, R.A.; Mose, L.E.; Mungall, A.J.; Naresh, R.; Naska, T.; Neder, L.; Noble, M.S.; Noss, A.; O’Neill, B.P.; Ostrom, Q.T.; Palmer, C.; Pantazi, A.; Parfenov, M.; Park, P.J.; Parker, J.S.; Perou, C.M.; Pierson, C.R.; Pihl, T.; Protopopov, A.; Radenbaugh, A.; Ramirez, N.C.; Rathmell, W.K.; Ren, X.; Roach, J.; Robertson, A.G.; Saksena, G.; Schein, J.E.; Schumacher, S.E.; Seidman, J.; Senecal, K.; Seth, S.; Shen, H.; Shi, Y.; Shih, J.; Shimmel, K.; Sicotte, H.; Sifri, S.; Silva, T.; Simons, J.V.; Singh, R.; Skelly, T.; Sloan, A.E.; Sofia, H.J.; Soloway, M.G.; Song, X.; Sougnez, C.; Souza, C.; Staugaitis, S.M.; Sun, H.; Sun, C.; Tan, D.; Tang, J.; Tang, Y.; Thorne, L.; Trevisan, F.A.; Triche, T.; Van Den Berg, D.J.; Veluvolu, U.; Voet, D.; Wan, Y.; Wang, Z.; Warnick, R.; Weinstein, J.N.; Weisenberger, D.J.; Wilkerson, M.D.; Williams, F.; Wise, L.; Wolinsky, Y.; Wu, J.; Xu, A.W.; Yang, L.; Yang, L.; Zack, T.I.; Zenklusen, J.C.; Zhang, J.; Zhang, W.; Zhang, J.; Zmuda, E. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164: 550-63.
[19]
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
[20]
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
[21]
Li X-B, Yang G, Zhu L, et al. Gastric Lgr5(+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. Cell Res 2016; 26: 838-49.
[22]
Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database--2009 Update. Nucleic Acids Res 2009; 37: D767-72.
[23]
Matthews L, Gopinath G, Gillespie M, et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009; 37: D619-22.
[24]
Schaefer CF, Anthony K, Krupa S, et al. PID: The pathway interaction database. Nucleic Acids Res 2009; 37: D674-9.
[25]
Cerami EG, Gross BE, Demir E, et al. Pathway commons, a web resource for biological pathway data. Nucleic Acids Res 2011; 39: D685-90.
[26]
Clarke C, Madden SF, Doolan P, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 2013; 34: 2300-8.
[27]
Gravendeel LAM, Kouwenhoven MCM, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69: 9065-72.
[28]
Reddy EP, Reynolds RK, Santos E, Barbacid M. A Point mutation is responsible for the acquisition of transforming properties by the t24 human bladder carcinoma oncogene. Nature 1982; 300: 149-52.
[29]
Ladenson RP, Schwartz SO, Ivy AC. Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma. Am J Med Sci 1949; 217: 194-7.
[30]
Hakomori SI, Murakami WT. Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci USA 1968; 59: 254-61.
[31]
Du G, Zhao B, Zhang Y, et al. Hypothermia activates adipose tissue to promote malignant lung cancer progression. PLoS One 2013; 8: e72044.
[32]
Baghy K, Tátrai P, Regős E, Kovalszky I. Proteoglycans in Liver Cancer. World J Gastroenterol 2016; 22: 379-93.
[33]
Rangel MP, de Sá VK, Prieto T, et al. Biomolecular analysis of matrix proteoglycans as biomarkers in non small cell lung cancer. Glycoconj J 2018; 35: 233-42.
[34]
Qian Z, Zhang G, Song G, et al. Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis. Oncotarget 2017; 8: 25500-12.
[35]
Zhu Y-H, Yang F, Zhang S-S, Zeng T-T, Xie X, Guan X-Y. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2013; 6: 2497-505.
[36]
Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells 2014; 32: 135-44.
[37]
Yue P, Lopez-Tapia F, Paladino D, et al. Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes In Vitro and In Vivo. Cancer Res 2016; 76: 652-63.
[38]
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
[39]
Lu L, Zeng J. Evaluation of K-Ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas. PLoS One 2017; 12: e0181532.
[40]
Schaefer L, Gröne HJ, Raslik I, et al. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int 2000; 58: 1557-68.
[41]
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015; 15: 540-55.
[42]
Iozzo RV, Chakrani F, Perrotti D, et al. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 1999; 96: 3092-7.
[43]
Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001; 92: 562-7.
[44]
Winsey SL, Haldar NA, Marsh HP, et al. A Variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60: 5612-6.
[45]
Weber CK, Sommer G, Michl P, et al. Biglycan Is Overexpressed in pancreatic cancer and induces G1-Arrest in pancreatic cancer cell lines. Gastroenterology 2001; 121: 657-67.
[46]
Köninger J, Giese NA, di Mola FF, et al. Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 2004; 10: 4776-83.
[47]
Niedworok C, Röck K, Kretschmer I, et al. Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer. PLoS One 2013; 8: e80084.
[48]
Bischof AG, Yüksel D, Mammoto T, Mammoto A, Krause S, Ingber DE. Breast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycan. Integr Biol 2013; 5: 1045-56.
[49]
Goldoni S, Seidler DG, Heath J, et al. An antimetastatic role for decorin in breast cancer. Am J Pathol 2008; 173: 844-55.
[50]
Svensson KJ, Christianson HC, Kucharzewska P, et al. Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 2011; 39: 1421-8.
[51]
Vallen MJE, Massuger LFAG, ten Dam GB, Bulten J, van Kuppevelt TH. Highly sulfated chondroitin sulfates, a novel class of prognostic biomarkers in ovarian cancer tissue. Gynecol Oncol 2012; 127: 202-9.
[52]
Momose T, Yoshimura Y, Harumiya S, et al. Chondroitin sulfate synthase 1 expression is associated with malignant potential of Soft tissue sarcomas with myxoid substance. Hum Pathol 2016; 50: 15-23.
[53]
Kalathas D, Theocharis DA, Bounias D, et al. Chondroitin synthases i, ii, iii and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Rep 2011; 4: 363-8.
[54]
Dennis JW, Pawling J, Cheung P, Partridge E, Demetriou M. UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim Biophys Acta 2002; 1573: 414-22.
[55]
Hofree M, Shen JP, Carter H, Gross A, Ideker T. Network-based stratification of tumor mutations. Nat Methods 2013; 10: 1108-15.
[56]
Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343: 1235681.
[57]
Julien S, Picco G, Sewell R, et al. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 2009; 100: 1746-54.
[58]
English NM, Lesley JF, Hyman R. Site-Specific de-N-glycosylation of CD44 can activate hyaluronan binding, and cd44 activation states show distinct threshold densities for hyaluronan binding. Cancer Res 1998; 58: 3736-42.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [210 - 221]
Pages: 12
DOI: 10.2174/1568009618666180706165845
Price: $58

Article Metrics

PDF: 35
HTML: 5